Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States.
The last earnings update was 18 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Denali Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Denali Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Denali Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Denali Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Denali Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Denali Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Denali Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Denali Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Denali Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 7x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. since March 2015. From March 2015 to August 2015, Dr. Watts acted as interim President, Chief Scientific Officer and Head of Research and Development of Denali Therapeutics Inc. Dr. Watts served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure, he led Genetech entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. His own laboratory focused on understanding mechanisms of neurodegeneration and on drug discovery for Alzheimer’s disease. He is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.
Ryan's compensation has increased whilst company is loss making.
Ryan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Denali Therapeutics management team is about average.
CFO & Treasurer
Chief Medical Officer & Head of Development
Chief Technical and Manufacturing Officer
Vice President of Legal
Head of Human Resources
Head of Biology Discovery
Head of Discovery
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Denali Therapeutics board of directors is about average.
Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?
Today we will look at DNLI’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … View our latest analysis for Denali Therapeutics
Is Denali Therapeutics Inc's (NASDAQ:DNLI) Balance Sheet Strong Enough To Weather A Storm?
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is DNLI growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital
Denali Therapeutics Inc (NASDAQ:DNLI): Time For A Financial Health Check
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does DNLI's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
What Should We Expect From Denali Therapeutics Inc's (NASDAQ:DNLI) Earnings Over The Next Few Years?
The latest earnings release Denali Therapeutics Inc's (NASDAQ:DNLI) announced in September 2017 showed that losses became smaller relative to the prrior year's level - great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts perceive Denali Therapeutics's earnings growth outlook over the next couple of years and whether the future looks brighter. … NasdaqGS:DNLI Future Profit Jan 11th 18 Although it’s useful to understand the rate of growth each year relative to today’s figure, it may be more valuable evaluating the rate at which the company is growing on average every year. … Future Earnings: How does DNLI's growth rate compare to its peers and the wider market2
What’s Ahead For Denali Therapeutics Inc (NASDAQ:DNLI)?
Check out our latest analysis for Denali Therapeutics What’s the catalyst for Denali Therapeutics's sector growth? … Denali Therapeutics recently delivered an industry-beating growth rate in earnings, which is a positive for shareholders. … However, if you’re relatively concentrated in biotech, you may want to value Denali Therapeutics based on its cash flows to determine if it is overpriced based on its current growth outlook.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson’s disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer’s disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.